Combinatorial approach to cancer immunotherapy: strength in numbers
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combinatorial approach to cancer immunotherapy: strength in numbers
Authors
Keywords
-
Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 100, Issue 2, Pages 275-290
Publisher
Wiley
Online
2016-06-03
DOI
10.1189/jlb.5ri0116-013rr
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low dose cyclophosphamide: Mechanisms of T cell modulation
- (2016) Mutsa Tatenda Madondo et al. CANCER TREATMENT REVIEWS
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
- (2016) Meng Michelle Xu et al. TRENDS IN IMMUNOLOGY
- Emerging immune checkpoints for cancer therapy
- (2015) Xiaodong Li et al. ACTA ONCOLOGICA
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
- (2015) Y. Liu et al. CLINICAL CANCER RESEARCH
- 511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
- (2015) G. Gibney et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD70: An emerging target in cancer immunotherapy
- (2015) J. Jacobs et al. PHARMACOLOGY & THERAPEUTICS
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Epigenetics Meets Immune Checkpoints
- (2015) Alessia Covre et al. SEMINARS IN ONCOLOGY
- Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
- (2015) Margaret K. Callahan et al. SEMINARS IN ONCOLOGY
- Antagonists of PD-1 and PD-L1 in Cancer Treatment
- (2015) Evan J. Lipson et al. SEMINARS IN ONCOLOGY
- Checkpoint blockade in combination with cancer vaccines
- (2015) Michael A. Morse et al. VACCINE
- First Immunotherapy Combo Approved for Cancer
- (2015) Cancer Discovery
- Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
- (2015) A. Zippelius et al. Cancer Immunology Research
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
- (2015) Isabelle Le Mercier et al. Frontiers in Immunology
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- (2015) Abhishek D. Garg et al. Frontiers in Immunology
- Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
- (2015) Jitka Fucikova et al. Frontiers in Immunology
- Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
- (2015) A Covre et al. OncoImmunology
- Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses
- (2015) Anna Vilgelm et al. OncoImmunology
- BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
- (2015) Cara L Haymaker et al. OncoImmunology
- A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab
- (2015) Ravi A Chandra et al. OncoImmunology
- Therapeutic Advances and Treatment Options in Metastatic Melanoma
- (2015) Douglas B. Johnson et al. JAMA Oncology
- Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
- (2015) Tara C Gangadhar et al. Journal for ImmunoTherapy of Cancer
- Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
- (2015) Venky Ramakrishna et al. Journal for ImmunoTherapy of Cancer
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer
- (2014) Vanessa Gauttier et al. INTERNATIONAL JOURNAL OF CANCER
- Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death
- (2014) Carolien A. Koks et al. INTERNATIONAL JOURNAL OF CANCER
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer
- (2014) Jinpu Yu et al. JOURNAL OF IMMUNOLOGY
- OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells To Exit Quiescence
- (2014) Sarah L. Buchan et al. JOURNAL OF IMMUNOLOGY
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic drugs as immunomodulators for combination therapies in solid tumors
- (2014) Luca Sigalotti et al. PHARMACOLOGY & THERAPEUTICS
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
- (2014) Nicholas M. Durham et al. PLoS One
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
- (2014) J. A. Wargo et al. Cancer Discovery
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
- (2014) S. Chen et al. Cancer Immunology Research
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
- (2014) Antonio M Grimaldi et al. OncoImmunology
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
- (2013) A. C. West et al. CANCER RESEARCH
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Danger signalling during cancer cell death: origins, plasticity and regulation
- (2013) A D Garg et al. CELL DEATH AND DIFFERENTIATION
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
- (2013) W. L. Redmond et al. Cancer Immunology Research
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection
- (2012) S P Grekova et al. CANCER GENE THERAPY
- CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
- (2012) C. Claus et al. CANCER RESEARCH
- Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies
- (2012) L. Hoenicke et al. CARCINOGENESIS
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- 4-1BB signaling beyond T cells
- (2011) Dass S Vinay et al. Cellular & Molecular Immunology
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
- (2011) Tae-Won Kang et al. NATURE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro
- (2010) Jürgen Sonnemann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
- (2010) Juan Dubrot et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
- (2010) J. Mitsui et al. CLINICAL CANCER RESEARCH
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TIM-3: A Novel Regulatory Molecule of Alloimmune Activation
- (2010) O. Boenisch et al. JOURNAL OF IMMUNOLOGY
- Therapy-Induced Senescence in Cancer
- (2010) Jonathan A. Ewald et al. JNCI-Journal of the National Cancer Institute
- Circulating mitochondrial DAMPs cause inflammatory responses to injury
- (2010) Qin Zhang et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
- (2010) Adam D. Cohen et al. PLoS One
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
- (2008) R. Houot et al. BLOOD
- Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules
- (2008) Sara J. Adair et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer
- (2008) Nithin D. Adappa et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now